Chemistry is an early-stage venture capital firm that focuses on Seed and Series A investments in standout software companies, particularly within fintech, infrastructure, developer tools, and B2B sectors. Their strategy involves a hands-on, highly engaged, and concentrated approach, with each partner making only two to three investments per year to provide intensive support and deep expertise to founders.
33% of their portfolio is in Healthcare. They made 6 investments in the last 12 months. Their most common stage is series-a (50% of deals). Average disclosed round size is $101.0M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
$350M
Top Stage
Series A
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| YYuzu Health | Series A | $35M | Apr 2026 |
 Didero | Series A | $30M | Feb 2026 |
 Decagon | Series D | $250M | Jan 2026 |
 Datacurve | Series A | $15M | Oct 2025 |
 Assort Health | Series B | $76M | Sep 2025 |
 Persona | Series D | $200M | Apr 2025 |
Top Co-Investors
First Round Capital2 shared
A*2 shared
Coatue Management2 shared
Index Ventures2 shared
Ribbit Capital2 shared
Headline1 shared
M12 (Microsoft)1 shared
Lightspeed Venture Partners1 shared
Felicis Ventures1 shared
Liquid 2 Ventures1 shared
Quiet Capital1 shared
Accel1 shared
Forerunner Ventures1 shared
Definition Capital1 shared
Starwood1 shared
Andreessen Horowitz1 shared
Avra1 shared
Bain Capital Ventures1 shared
T.Capital1 shared
Founders Fund1 shared
Last updated: 10 April 2026